| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Nuclear protein pirin. The compound inhibits the interaction between pirin and Bcl3.
|
|---|---|
| ln Vitro |
Nuclear factor I/CCAAT box transcription factor (NFI/CTF) is present in pirin, a nuclear protein. Pirin proteins are thought to be a member of the cupin superfamily because of their great degree of conservation among prokaryotes, plants, fungus, and mammals. The TPh A (20 μM; 5 hr) decreases the quantity of Bcl3 bound to pirin and hinders the interaction with glutathione S-transferase (GST) purLldown assay. HEK293T cells transfected with Myc and pirin-His6 vectors for 43 hours showed differences between pirin and Bcl3 [1]. While TPh A (0-100 μM; 48 hours) is active against MCF7, MDA-MB231, HeLa, DU145, HepG2, A549, HT1080, WM266-4, and SK, it lacks potent cytotoxic activity against many other human cancer cell lines. The IC50 values for MEL-28 cells are >50 μM, while those for PC3 HL60 and HT29 cells are 27 μM, 20 μM, and 26 μM, respectively [1]. WM266-4 and SK-MEL-28 cells' ability to migrate is inhibited by TPhA (0-50 μM; 48 hours) in a concentration-dependent manner [1].
In vitro, TPh A inhibits the interaction between pirin and Bcl3. It shows no potent cytotoxic activity against many human cancer cell lines after 48 hours of treatment. However, it dose-dependently inhibits melanoma cell migration by suppressing SNAI2 promoter activity. It binds specifically to pirin with a Ki of 0.6 μM. |
| ln Vivo |
While specific in vivo studies for TPh A are less detailed, related compounds have been used to study wound healing. For example, a novel small compound (related to TPh A) accelerated dermal wound healing in mice by modifying infiltration, proliferation, and migration of distinct cellular components. TPh A's in vivo role in cancer and other pathways is an area of ongoing research.
|
| Enzyme Assay |
The binding affinity of TPh A to pirin is typically determined using isothermal titration calorimetry (ITC) or surface plasmon resonance (SPR), yielding a Ki or Kd value of 0.6 μM. These methods measure the direct interaction between the purified pirin protein and the compound to quantify their binding strength and stoichiometry.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: MCF7, MDA-MB231, HeLa, DU145, HepG2, A549, HT1080, WM266-4, and SK-MEL-28 cells Tested Tested Concentrations: 0-100 μM Incubation Duration: 48 hrs (hours) Experimental Results: Did not exert any potent cytotoxic activity against many human cancer cell lines. Cellular studies are performed using melanoma cell lines. Cells are treated with varying concentrations of TPh A for up to 48 hours. Cell viability is assessed using standard assays like MTT or CellTiter-Glo. Cell migration is evaluated using a wound-healing assay or a Boyden chamber assay, and the expression of SNAI2 is measured via qPCR or Western blot. |
| Animal Protocol |
In vivo efficacy is typically evaluated using mouse xenograft models where melanoma cells are implanted subcutaneously. TPh A is administered (route and dose depend on the study) to assess its effect on tumor growth and metastasis. Tissue samples are collected for histopathological and molecular analysis to confirm target engagement and mechanism.
|
| ADME/Pharmacokinetics |
Specific ADME data for TPh A are not widely published. Its solubility in DMSO (10 mM) and stability as a solid at -20°C are documented. As a small molecule, its behavior in vivo would be subject to standard drug metabolism and pharmacokinetic principles, but dedicated studies would be required for detailed characterization.
|
| Toxicity/Toxicokinetics |
Available data indicate that TPh A does not exert potent cytotoxic activity against many human cancer cell lines after 48 hours of treatment, suggesting a favorable safety profile in vitro. Comprehensive in vivo toxicology data are not available, as the compound is used primarily for research purposes. Standard laboratory safety precautions are advised.
|
| References | |
| Additional Infomation |
TPh A is a research compound and is not approved for clinical use. It serves as a valuable chemical probe to study the biological function of pirin, particularly its role in cancer cell migration and metastasis. The compound has been used in studies elucidating the pirin-Bcl3 signaling axis and its potential as a therapeutic target in melanoma.
|
| Molecular Formula |
C21H21NO3S2
|
|---|---|
| Molecular Weight |
399.53
|
| Exact Mass |
399.096
|
| CAS # |
21306-65-0
|
| PubChem CID |
9583267
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
6.484
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
577
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC=C(C=C1)S(=O)(=O)N=S(C)C2=CC=C(C=C2)OCC3=CC=CC=C3
|
| InChi Key |
IMUPOWQOXOCVBN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H21NO3S2/c1-17-8-14-21(15-9-17)27(23,24)22-26(2)20-12-10-19(11-13-20)25-16-18-6-4-3-5-7-18/h3-15H,16H2,1-2H3
|
| Chemical Name |
(NE)-4-methyl-N-[methyl-(4-phenylmethoxyphenyl)-λ4-sulfanylidene]benzenesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (625.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5029 mL | 12.5147 mL | 25.0294 mL | |
| 5 mM | 0.5006 mL | 2.5029 mL | 5.0059 mL | |
| 10 mM | 0.2503 mL | 1.2515 mL | 2.5029 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
